Apollon

iOmx Therapeutics to present new data on lead programs and I/O target screening platform at AACR 2024

Retrieved on: 
Wednesday, April 3, 2024
Apollon, Apoptosis, Tumor microenvironment, Cancer, Abstract, AACR, Therapy, Escape Room, Pharmaceutical industry

MARTINSRIED, Germany and MUNICH, Germany, April 03, 2024 (GLOBE NEWSWIRE) -- iOmx Therapeutics AG (iOmx), a clinical-stage biopharmaceutical company translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs, today announces that it will present new data on its lead I/O drug candidates OMX-0407 and IOMX-0675, plus its proprietary iOTarg™ screening platform at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place from April 5-10, 2024, in San Diego, California.

Key Points: 
  • "We are excited to share updates on our two lead I/O programs targeting a broad range of solid tumor indications and our high-throughput target screening platform – iOTarg.
  • Through tyrosine kinase signaling, OMX-0407 interferes with cell cycle regulation and cancer cell proliferation.
  • Complementary to this direct mode of action, OMX-0407 also potentiates tumor cell apoptosis in response to death receptor ligands including tumor necrosis factor through salt inducible kinase signaling.
  • With this dual mode of action, OMX-0407 has shown striking single-agent efficacy in multiple pre-clinical tumor models.

South Carolina-Based Wealth Management Group Strengthens National Presence in 2023 Expansion

Retrieved on: 
Wednesday, January 24, 2024
Asset Management, Professional Services, Finance, Apollon, Senior, Citywire, Attention, RIA, Growth

“To succeed in the long term, it takes so much more than promises and platitudes to win the talent you need.

Key Points: 
  • “To succeed in the long term, it takes so much more than promises and platitudes to win the talent you need.
  • “We are fortunate to have built a strong network of partner firms that align with our goals in just five years since our founding.
  • We are excited to continue the rapid growth and expansion momentum into 2024 and beyond.”
    2023 also saw Apollon Wealth Management’s hiring of industry veteran Teresa Matthews-Fletcher as Senior Vice President of Operations, who has assisted in the firm’s recruiting efforts.
  • The pace of Apollon’s advancements earned the attention of international industry publication Citywire, which named Apollon the fastest-growing RIA in South Carolina on the outlet’s prestigious “50 Growers Across America” list.

EQS-News: iOmx Therapeutics attends 2024 J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, December 21, 2023
Apollon, CBO, Conference, Therapy, Pharmaceutical industry

iOmx Therapeutics attends 2024 J.P. Morgan Healthcare Conference

Key Points: 
  • iOmx Therapeutics attends 2024 J.P. Morgan Healthcare Conference
    The issuer is solely responsible for the content of this announcement.
  • iOmx Therapeutics attends 2024 J.P. Morgan Healthcare Conference
    Martinsried / Munich, Germany, December 20, 2023 - iOmx Therapeutics AG (iOmx), a clinical-stage biopharmaceutical company translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs, today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
  • Dr. Apollon Papadimitriou, CEO and Dr. Nils Debus, CBO, will be available on site and throughout the week for networking, partnering and one-to-one meetings.

EQS-News: iOmx Therapeutics attends upcoming scientific and industry conferences

Retrieved on: 
Tuesday, November 7, 2023
Apollon, Therapy, SITC, Immunotherapy, SIK, Society for Immunotherapy of Cancer, Cancer, CBO, Annual general meeting, Poster, Pharmaceutical industry, Nightclub

Martinsried / Munich, Germany, November 1, 2023 - iOmx Therapeutics AG (iOmx), a clinical-stage biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced its participation at two upcoming scientific and industry conferences: Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting and BIO-Europe.

Key Points: 
  • Martinsried / Munich, Germany, November 1, 2023 - iOmx Therapeutics AG (iOmx), a clinical-stage biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced its participation at two upcoming scientific and industry conferences: Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting and BIO-Europe.
  • 1 – 5 November 2023, San Diego, USA
    The poster describes the development of a response prediction biomarker signature for the orally available first-in-class SIK (salt-inducible kinase) inhibitor lead product candidate OMX-0407.
  • 6 – 8 November 2023, Munich, Germany
    Dr. Apollon Papadimitriou, CEO and Dr. Nils Debus, CBO, will be on site and available for meetings.
  • To request a meeting at the event in Munich, please use the partneringONE® system .

Apollon Wealth Management Bolsters Sarasota Office with Key Appointments

Retrieved on: 
Wednesday, October 11, 2023
Personal Finance, Finance, Banking, Professional Services, Asset Management, Alex Brown, RBC, Vanderbilt University, Engineering, Deutsche Bank, Interior design, Tourism, Apollon, Wood

Apollon Wealth Management (Apollon) proudly announces North Carolina-based advisors, Wesley Davis and Jeff Wood, have joined the Adi Dassler International Family Office (ADIFO) of Apollon.

Key Points: 
  • Apollon Wealth Management (Apollon) proudly announces North Carolina-based advisors, Wesley Davis and Jeff Wood, have joined the Adi Dassler International Family Office (ADIFO) of Apollon.
  • “The ADIFO team is comprised of seasoned experts in the wealth management field,” said Michael Dolberg, Founder and CEO of Apollon.
  • “I couldn’t be happier to welcome Wesley Davis and Jeff Wood to ADIFO,” said Allen Johnson, Founding Partner of Adi Dassler International Family Office.
  • To learn more about Apollon Wealth Management, please visit https://apollonwealthmanagement.com/ .

EQS-News: iOmx Therapeutics appoints Dr. Nils Peter Debus as Chief Business Officer

Retrieved on: 
Tuesday, September 5, 2023
Apollon, Myelocyte, Duke University, Business development, Therapy, Neoplasm, Cancer, Doctor of Philosophy, Schering AG, Humboldt University of Berlin, Boehringer Ingelheim, Patent, CBO, Growth, Schering, BD, Fine chemical, Bayer

Martinsried / Munich, Germany, September 5, 2023 - iOmx Therapeutics AG (iOmx), a clinical stage biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the appointment of Dr. Nils Peter Debus as Chief Business Officer (CBO) to drive the company’s new stage of growth.

Key Points: 
  • Martinsried / Munich, Germany, September 5, 2023 - iOmx Therapeutics AG (iOmx), a clinical stage biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the appointment of Dr. Nils Peter Debus as Chief Business Officer (CBO) to drive the company’s new stage of growth.
  • Dr. Debus is an accomplished life science leader with 27 years of industry experience and an outstanding track record in Business Development & Licensing.
  • Dr. Apollon Papadimitriou, CEO of iOmx, said: “Nils brings us significant strategic business expertise with a proven success in building partnerships and executing transformative collaborations and acquisitions.
  • Dr. Debus is a microbiologist by training and holds a PhD in embryonic stem cell research from Humboldt University (Berlin, Germany).

Apollon Wealth Management Brings In Midwest Wealth Management Firm Piershale Financial Group

Retrieved on: 
Wednesday, August 23, 2023
Finance, Consulting, Banking, Professional Services, Asset Management, RIA, DBA, Financial adviser, Apollon

Apollon Wealth Management (“Apollon”) is pleased to announce the addition of Piershale Financial Group (“Piershale”) to its growing network of wealth management offices across the U.S.

Key Points: 
  • Apollon Wealth Management (“Apollon”) is pleased to announce the addition of Piershale Financial Group (“Piershale”) to its growing network of wealth management offices across the U.S.
  • The new DBA, Piershale Financial Group of Apollon, will be part of Apollon’s SEC-registered RIA firm.
  • Apollon is a leading full-service wealth management firm and will provide Piershale clients with access to innovative investment solutions, an elite service team and cutting-edge technology.
  • Wealth advisors Ben Barzideh, ChFC®, RFC®, and Matt Nadeau, CFA®, RFC®, will also join Apollon, bringing an additional combined 40 years of wealth management expertise.

Apollon and MIT Commence Collaboration to Develop Continuous Non-Invasive Glucose Monitoring Technology

Retrieved on: 
Monday, August 21, 2023
Medical Supplies, Health, Start-Up, Diabetes, Professional Services, University, Education, Clinical Trials, CGM, Inc., Biological engineering, Science Advances, Asan Medical Center, Department of Mechanical Engineering, Imperial College London, MIT, Bangladesh Technical Education Board, Mechanical, MARD, Miniaturization, Samsung, Blood, Himawari (satellites), FDA, Skin, Massachusetts Institute of Technology, Medical device, Apollon

Dr. Peter So, Professor of Mechanical and Biological Engineering and Director of the MIT LBRC, and Dr. Jeonwoong Kang of the Department of Mechanical Engineering will lead the collaboration.

Key Points: 
  • Dr. Peter So, Professor of Mechanical and Biological Engineering and Director of the MIT LBRC, and Dr. Jeonwoong Kang of the Department of Mechanical Engineering will lead the collaboration.
  • As a result of Apollon's expertise in Raman diagnostics and spectrometer miniaturization, MIT will invite Dr. Youngkyu Kim of Apollon as a visiting scientist.
  • Dr. Kang published a paper in the prestigious journal Science Advances in 2020 that directly measured glucose concentration without drawing blood by irradiating the skin with laser light.
  • It was funded by the National Institutes of Health and Samsung Advanced Institute of Technology.

Tier 1 Chinese Suppliers Lead the Charge in Developing Innovative Intelligent Cockpit Products for the Global Automotive Market: 2023

Retrieved on: 
Thursday, July 27, 2023
Apollon, CMS, Huawei, Magneti Marelli, Auto Shanghai, Lidar, Continental, Panasonic, Neusoft, SOA, Valeo, Theft, LCC, Perception, 3D, Touchless knockout, Orientation, AVP, Intelligence, AR, Safety, ACC, BSD, Drive, AEB, Tier 1, HMI, SOC, HUAWEI, Eye, Algorithm, BOX, ADAS, Research, Fraud, Pedestrian, V2X, GPT, OTA, Qualcomm, Aptiv, Denso, AVM, Ryzen, AI, RGB, Video game, Mobile phone, Instrumentation, Television, Visteon

DUBLIN, July 27, 2023 /PRNewswire/ -- The "Leading Tier1 Suppliers' Intelligent Cockpit Business Research Report,2023 (Chinese Players)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 27, 2023 /PRNewswire/ -- The "Leading Tier1 Suppliers' Intelligent Cockpit Business Research Report,2023 (Chinese Players)" report has been added to ResearchAndMarkets.com's offering.
  • Research on tier 1 suppliers' cockpit business: new innovative intelligent cockpit products highlight multi-domain integration, multimodal interaction, and ever higher functional integration.
  • While improving the computing power, Neusoft C5 enables efficient integration of basic vehicle functions, gateways, body control, intelligent cockpit, and other extended functions.
  • In the trend for multi-domain and central domain controllers, Tier 1 suppliers are trying hard to deploy function integrated products.

Global Leading Tier1 Suppliers' Intelligent Cockpit Business Research Report 2023

Retrieved on: 
Tuesday, July 11, 2023
Apollon, CMS, Huawei, Magneti Marelli, Auto Shanghai, Original equipment manufacturer, Lidar, Continental, Panasonic, Neusoft, SOA, Valeo, LCC, Perception, 3D, Orientation, ZF, AVP, Intelligence, AR, Safety, ACC, BSD, Drive, AEB, Tier 1, HMI, SOC, Algorithm, BOX, ADAS, Research, Pedestrian, V2X, Foreign, GPT, OTA, Qualcomm, Wind, Aptiv, Denso, AVM, Ryzen, AI, RGB, WeRide, Video game, Instrumentation, Retail, Fine chemical, Visteon

DUBLIN, July 11, 2023 /PRNewswire/ --The "Leading Tier1 Suppliers' Intelligent Cockpit Business Research Report, 2023 (Foreign Players)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 11, 2023 /PRNewswire/ --The "Leading Tier1 Suppliers' Intelligent Cockpit Business Research Report, 2023 (Foreign Players)" report has been added to ResearchAndMarkets.com's offering.
  • Research on tier 1 suppliers' cockpit business: new innovative intelligent cockpit products highlight multi-domain integration, multimodal interaction, and ever higher functional integration.
  • While improving the computing power, Neusoft C5 enables efficient integration of basic vehicle functions, gateways, body control, intelligent cockpit, and other extended functions.
  • In April 2023, they jointly announced the new-generation intelligent cockpit 4.0 which creatively integrates in-cabin intelligence, vehicle services and related ecosystems into one middleware, a disruptive cockpit development mode.